ACSL5 and lung cancer: ACSL5‐downregulated lung cancer cells had less or no sensitivities in response to lysoPC, including exogenous lysoPC‐induced alterations of mitochondrial morphology and function, long‐chain FA mitochondrial beta‐oxidation, ROS productions and those lipid metabolisms.